Cartesian Therapeutics
Logotype for Cartesian Therapeutics Inc

Cartesian Therapeutics (RNAC) investor relations material

Cartesian Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cartesian Therapeutics Inc
Q3 2026 earnings summary5 Nov, 2026

Executive summary

  • Descartes-08 is advancing in Phase 3 AURORA for myasthenia gravis (MG), with a 1Q27 data readout targeted and a BLA filing planned for mid-2027; Phase 2 TRITON is evaluating myositis.

  • Cash, cash equivalents and restricted cash totaled $124.7M at September 30, 2026, and are expected to fund planned operations into 2028, including completion of AURORA.

  • Q3 net loss narrowed to $11.5M from $35.9M, chiefly reflecting non-cash fair-value gains on CVR and derivative liabilities, while trial spending increased.

Financial highlights

  • Q3 revenue was $0 versus $0.5M in Q3 2025; 9M revenue was $0.1M versus $1.85M, reflecting lower grant revenue and no collaboration or license revenue.

  • Q3 operating expenses were $25.0M, up 16% YoY; R&D was $15.6M versus $13.8M and G&A was $9.4M versus $7.7M.

  • Q3 operating loss was $25.0M versus $21.1M; 9M operating loss was $80.7M versus $64.8M.

  • Q3 net loss was $11.5M versus $35.9M; 9M net loss was $34.9M versus $37.7M. Q3 included $10.7M CVR and $3.3M derivative fair-value gains.

  • 9M operating cash use was $70.9M versus $56.2M; investing cash use was $0.7M versus $5.0M.

Outlook and guidance

  • AURORA data readout is targeted for 1Q27, followed by a BLA filing planned for mid-2027.

  • TRITON subset data and HELIOS data are expected in 1H27; TRITON results are intended to inform the potential path to a pivotal myositis trial.

  • Current cash resources are expected to support planned operations into 2028.

  • Operating losses and R&D and G&A expenses are expected to continue increasing; product-sales revenue is not expected for at least several years, and profitability may never be achieved.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Cartesian Therapeutics earnings date

Logotype for Cartesian Therapeutics Inc
Q4 20268 Mar, 2027
Cartesian Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Cartesian Therapeutics earnings date

Logotype for Cartesian Therapeutics Inc
Q4 20268 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for the treatment of autoimmune diseases and cancer. The company uses its proprietary RNA cell therapy platform to engineer immune cells with therapeutic potential. Cartesian’s therapies are designed to target specific disease pathways, aiming to provide more effective treatments with fewer side effects compared to traditional approaches. The company is headquartered in Gaithersburg, Maryland, and its shares are listed on the NASDAQ.